Skip to main content

Table 2 Overview of (potentially cholinergically mediated) AEs reported by elderly subjects

From: Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study

MedDRA-preferred term

Placebo

n=14

15 mg

n=9

20 mg

n=9

25 mg

n=9

35 mg

n=2

35 mg + up-titration

n=7

All HTL0018318

n=36

All AEs

8 (57.1)

7 (77.8)

7 (77.8)

9 (100.0)

2 (100.0)

7 (100.0)

32 (88.9)

All cholinergic AEs

2 (14.3)

1 (11.1)

5 (55.6)

7 (77.8)

2 (100)

7 (100)

22 (61.1)

Hypertension

0

0

0

1

1

1

3 (8.3)

Nausea

0

1 (11.1)

1 (11.1)

2 (22.2)

0

0

4 (11.1)

Diarrhoea

0

0

0

1 (11.1)

0

0

1 (2.8)

Vomiting

0

0

0

0

0

0

0

Constipation

1 (7.1)

0

0

0

0

0

0

Hypersalivation

0

0

0

0

0

0

0

Hyperhidrosis

0

0

3 (33.3)

5 (55.6)

0

2 (28.6)

10 (27.8)

Chills

0

0

0

1 (11.1)

0

4 (57.1)

5 (13.9)

Cold sweat

0

0

0

0

1 (50.0)

2 (28.6)

3 (8.3)

Feeling cold

1 (7.1)

0

1 (11.1)

2 (22.2)

1 (50.0)

2 (28.6)

6 (16.7)

Feeling hot

0

0

0

2 (22.2)

0

0

2 (5.6)

Feeling of body temperature change

0

0

0

1 (11.1)

0

0

1 (2.8)

Hot flush

0

0

2 (22.2)

1 (11.1)

0

2 (28.6)

5 (13.9)

Peripheral coldness

0

0

0

0

1 (50.0)

0

1 (2.8)

Piloerection

0

0

0

0

0

0

0

Insomnia

0

0

1

0

0

0

1 (2.8)

Dizziness

1

0

0

3

0

0

3 (8.3)

Muscle spasm

0

0

1

0

0

0

1 (2.8)

  1. Data are shown as number of subjects reporting adverse events (percentage of subjects)